Possible Pathogenetic Relationship between Fabry Disease and Renal Cell Carcinoma

Fabio Pagni\textsuperscript{a} Federico Pieruzzi\textsuperscript{b} Stefano Zannella\textsuperscript{a} Antonella Di Giacomo\textsuperscript{b} Giorgio Bovo\textsuperscript{a} Franco Ferrario\textsuperscript{a} Giacomo Torti\textsuperscript{b} Rodolfo Rivera\textsuperscript{b} Emma Assi\textsuperscript{c} Federica Viglione\textsuperscript{e} Manuela Nebuloni\textsuperscript{d}

Departments of \textsuperscript{a}Pathology and \textsuperscript{b}Nephrology, San Gerardo Hospital, University of Milan-Bicocca, Monza, Departments of \textsuperscript{c}Pharmacology and \textsuperscript{d}Pathology, Sacco Hospital, University of Milan, Milan, and \textsuperscript{e}Laboratory of Histology, Institute of Clinical Physiology, CNR, Pisa, Italy

Key Words
Fabry disease • Renal cell carcinoma • Zebra bodies • Renal biopsy

Abstract
The occurrence of renal cell carcinoma (RCC) in Fabry disease (FD) is a rare event. We report a deep ultrastructural study of RCC in a patient with a previous histological diagnosis of FD. In order to highlight analogies and differences between the two histological samples, we used the nephrectomy specimen as a ‘repeat biopsy’, making a dynamic analysis of the evolution of the disease-related kidney damage. Secondly, a comparative ultrastructural analysis between non-neoplastic tissue and cancer demonstrated for the first time the presence of zebra bodies in the tumor cells. Finally, a hypothetical speculation about the relationship between the lysosomal accumulation, the oxidative damage and the genesis of the tumor was performed. The link connected the accumulation of glycosphingolipid globotriaosylceramide, characteristic of FD, with the expression of CD74 and macrophage migration inhibitory factor that may play an important role in tumorigenesis regulated by the Von Hippel-Lindau/hypoxia-inducible factor 1α pathway.

Introduction

Fabry disease (FD) is an X-linked syndrome caused by the missing activity of the enzyme α-galactosidase A which results in a progressive and systemic accumulation of glycosphingolipid globotriaosylceramide (Gb3). In most cases, the advanced disease leads to a progressive deterioration of kidney function due to the presence of typical deposits in renal cells, especially podocytes. These deposits, which are called myelin bodies or zebra bodies, are best shown thanks to transmission electron microscopy (TEM) and could have different sizes and shapes. The occurrence of renal cell carcinoma (RCC) in FD is an rare event. Only two other cases of (bilateral) RCC in a genetically confirmed FD have been reported in the literature [1, 2]. No etiologic correlation between FD and tumor development was demonstrated. Moreover, these tumors did not present peculiar features compared with conventional (sporadic and hereditary) forms.

F. Pagni and F. Pieruzzi contributed equally to this paper.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2012 S. Karger AG, Basel
0250-8095/12/0366–0537/00/0
Accessible online at:
www.karger.com/ajn

Dr. Fabio Pagni
Department of Pathology, San Gerardo Hospital, University of Milan-Bicocca
IT–20900 Monza (Italy)
E-Mail fabio.pagni@unimib.it

© 2012 S. Karger AG, Basel
Published online: November 29, 2012
Am J Nephrol 2012;36:537–541
DOI: 10.1159/000345465
Case Report

After a diagnosis of FD in her third son, a 45-year-old Peruvian female patient was found to have proteinuria (286 mg/24 h, albuminuria 154 mg/24 h, creatinine clearance 160 ml/min) associated with neurosensory hearing loss, corneal whirling and paresthesias. α-Galactosidase A enzyme activity in plasma leukocytes was low (26 nmol/h/mg; normal range: 30.2–107.5). The patient underwent renal biopsy, which suggested an FD diagnosis (fig. 1). A genetic analysis (polymerase chain reaction and direct DNA sequencing) found a new mutation both in her son’s skin fibroblasts and her peripheral blood. This spot mutation (heterozygosis, c.4C>T) causes a Gln2Stop non-sense mutation. Sequencing analysis of exon 1 showed presence of the polymorphism g.1170C>T [3]. Angiotensin-converting enzyme inhibitor and enzyme replacement therapy (ERT) was planned, but the patient did not optimally comply with the treatment during the follow-up. However, she underwent annual ultrasound examination. Six years later, a hyperechogenic nodule in the right kidney appeared. Computerized tomography showed a solid and exophytic lesion in the middle-upper pole of the kidney (fig. 2a). There was no clinical evidence of renal failure. The patient underwent a nephrectomy, and the lesion was diagnosed as an RCC. After the surgery, we observed a progressive worsening of creatinine clearance (55 ml/min), and a tendency to higher pressure levels. For these reasons, angiotensin-converting enzyme inhibitor therapy was confirmed, with a strong recommendation to start ERT.

Renal Biopsy Findings

For the histological analysis, a 1.5-cm-long renal core biopsy was fixed with 10% buffered formalin and afterward paraffin embedded. 3-μm-thick sections were cut from the block and set for hematoxylin-eosin and histochemical stains. A little fragment of the biopsy was frozen and sent for immunofluorescence (IF). A third little sample was taken for TEM, fixed in glutaraldehyde, dehydrated and embedded in Epon. Resin-embedded sections were stained with toluidine blue. Histological sections revealed the presence of 15 glomeruli with absence of mesangial alterations and normal basal membrane (fig. 1a); 2 out of 15 glomeruli were totally sclerotic. Segmental sclerosis was focally present (fig. 1a). Podocytes showed mild bulging and vacuolated aspects (fig. 1a). Some tubular cells with foamy cytoplasm were found. At high-
power field, toluidine blue staining revealed inclusions suspicious of zebra bodies (fig. 1b). IF (IgG, IgA, IgM, C3, C1q, fibrinogen, kappa and lambda immunoglobulin light chains) resulted completely negative. TEM showed rarefaction and vacuolization of visceral epithelium and endothelial cells, with irregularly thick basal membrane and frequent thin shares. Zebra bodies with cytoplasmic localization were found with a focal pattern of distribution in visceral (fig. 1c), parietal (fig. 1d) and tubular (fig. 1e) cells. No inclusion in endothelial cells was present.

Nephrectomy Findings

A 10 × 4.5 × 3 cm right nephrectomy specimen was submitted for histological analysis. The kidney showed a 2.7-cm maximum diameter nodular mass with yellow cut surface located in the central region (fig. 2b). Histologically, the tumor was constituted by clear cells with classic features of conventional RCC (Fuhrman grade 2; fig. 2c). The peritumoral tissue showed some totally sclerotic glomeruli; segmental sclerosis with visceral epithelial hypertrophy was appreciable with a more diffuse pattern than in renal biopsy. Cytoplasmic vacuolization of the tubular epithelium and minimal peritubular and vascular fibrosis were reported. IF was completely negative again. EM showed Gb3-rich lipidic lysosomal inclusions and lamellar structures in podocytes, parietal and tubular cells. Myelin-like structures and tiny Gb3 inclusions were evident also in mesangial cells (fig. 2d). In contrast to the first biopsy, the Gb3 inclusions were present also in the endothelial cells of the glomerular and interstitial vessels (fig. 2e). TEM revealed Gb3 lysosomal inclusions in tumor clear cells (fig. 2f) and endothelial cells. Finally, the nephrectomy specimen was stained with CD74 (immunohistochemistry LN2 at 1:50 dilution, Dako, Glostrup, Denmark) and macrophage migration inhibitory factor (MIF sc_20121 at 1:100 dilution, Santa Cruz Biotechnology, Santa Cruz, Calif., USA). CD74 (fig. 3a) and its ligand MIF (fig. 3b) displayed a prominent membrane localization at immunohistochemistry in tumor cells, as previously described [4]. Moreover, patchy reactivity was also evident in glomeruli and tubules (fig. 3c, d).
Discussion

Blanco et al. [2] reported a case of bilateral conventional RCC in a patient with chronic renal failure, diagnosed as FD only after the histological examination of the resected kidney. Cassiman et al. [1] described a bilateral multifocal RCC (papillary and clear cell type) in a kidney without the typical morphological alterations of FD. Both patients were males. We had the exceptional possibility to study a female patient with a first renal biopsy diagnosed as FD and a second specimen from nephrectomy that we could consider as 'repeat' biopsy. Moreover, no ERT was performed during the period between the two histological examinations, so we had the opportunity to study the natural history of FD. Foamy podocytes were present in the first renal biopsy, while in the second specimen similar vacuoles were easily detected also in the tubular cells. Focal segmental sclerosis was already present at the time of diagnosis; 6 years later, this finding was even more evident, probably because of the chronic evolution of untreated FD. The arteriole walls were a little more thickened in the second specimen, while we did not detect a severe vascular injury. The ultrastructural findings of our study were the most interesting features. In the first biopsy, inclusions were easily recognizable in epithelial cells. No alteration was evident in the endothelium. Instead, endothelial inclusions in nephrectomy were tiny, but frequent in glomeruli, interstitium and around the tumor. So, the first ‘take home message’ was that despite a normal renal function the kidney damage had a significant progressive evolution that could justify repeat biopsy as an important clinical instrument for patient management [3]. The second key point of our report was the possible pathogenetic relationship between FD and RCC. Were the zebra bodies in RCC cells only an epiphenomenon of a constitutive enzymatic deficit or, alternatively, a promoting factor involved in oncogenesis? Supporting this second hypothesis, many types of glycosphingolipids and gangliosides were found in a variety of renal non-neoplastic diseases (polycystic kidney disease, acute kidney injury, glomerulonephritis and diabetic nephropathy) and in RCC cells [5]. In fact, glycosphingolipids are thought to promote cell proliferation and, thus, tumor growth [6]. In vitro models had just shown that Gb3 are related to oxidative stress damage in a dose-dependent manner [7]. Interestingly, we know that the most powerful trigger in RCC development is oxidative damage (through Von Hippel-Lindau/hypoxia-inducible factor 1α – VHL/HIF pathway) [8]. In vivo models are still unavailable, but a preliminary investigation in FD patients under ERT found that elevated Gb3 levels are strongly related to decreased antioxidant defenses and increased levels of inflammatory cytokines ( interleukin-6 and tumor necrosis factor-α) [9]. Moreover, Lyso-Gb3
was recently shown to increase transforming growth factor-β₁ production and CD74 expression in cultured renal cells. Lyso-Gb₃ is globotriaosylsphingosine, a glycolipid accumulated in FD that is more water soluble than Gb₃ [10]. Accumulating evidence has found that CD74 is up-regulated in various kinds of cancers, implying that CD74 may play an important role in tumorigenesis. Genomic studies and immunohistochemical analyses suggest that CD74 is involved in tumor growth and metastasis [11]. The CD74 ligand (MIF) has also been proposed to play a role in renal cancer, regulated by the VHL/HIF pathway and overexpressed because of the loss of VHL [4]. So, we tested CD74 and MIF immunohistochemical expression in our nephrectomy specimen confirming their upregulation especially in tumor cells. We suggest a physiopathological link between Gb₃ accumulation, oxidative stress and oncogenesis (VHL/HIF pathway) according to the hypothesis that high levels of MIF, secreted by RCC cells, activate a positive signaling cascade through the engagement of the cell surface receptors CD74. Although we present a single case, the possible correlation between RCC and FD is further sustained by the early onset of this tumor (50 years; median age for RCC 60–70 years) [12] and its rapid growth. As already proposed [13], only prospective studies will be able to clarify if FD patients have an incremental oncologic risk. Considering the bilateral presentation of the previous FD-related RCC in the literature, we will monitor the patient with a strong and seriated follow-up.

Acknowledgements

Special thanks to Antonella Tosoni, technician (University of Milan, Sacco Hospital) for her wonderful contribution to the ultrastructural analysis, and to Serena Buscone, BD (University Milan Bicocca), and Mattia Bugatti, technician (University of Brescia), for their expertise. Thanks to Dr. Marco Grasso, MD (San Gerardo Hospital, Monza), for the surgical management of the patient.

Disclosure Statement

The authors declare no competing interest or conflict of interest.

References